The ALS Therapy Development Alliance (ALS TDI) has published an article in Nature Genetics linking “unbiased gene expression profiling” to the identification of a potential ALS therapy. The work further implicates the immune system in ALS; the researchers report that blocking the interaction between two molecules in the immune system using an inhibitory molecule can considerably slow the disease in the ALS mouse. The inhibitor molecule, ALS TDI 00846, will be advanced to clinical trials as soon as possible. This work was made possible by multi-year grants from the Muscular Dystrophy Association, the Department of Defense, and the RGK Foundation.
Click here to read more.Share this: